Verastem, Inc. (VSTM)

Trade VSTM now with
8/29/2018 4:09:24 PM Verastem Oncology Appoints Robert Gagnon As CFO
6/16/2018 6:41:36 AM Verastem Oncology Presents Duvelisib Data At EHA 2018 Annual Meeting
6/14/2018 4:04:03 PM Verastem Oncology Announces $43 Mln Offering Of Common Stock
5/16/2018 9:30:32 AM Verastem Oncology Announces Pricing Of Public Offering Of 7.78 Mln Shares At $4.50/Shr
4/9/2018 4:13:59 PM Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/9/2018 3:02:23 AM Verastem : FDA Accepts NDA For Duvelisib And Grants Priority Review
3/13/2018 7:10:55 AM Verastem FY Net Loss $67.8 Mln Or $1.76/Shr Vs Loss Of $36.4 Mln Or $0.99/Shr Last Year
2/7/2018 7:16:05 AM Verastem Submits NDA For Duvelisib For Treatment Of Patients With Relapsed Or Refractory CLL/SLL And Follicular Lymphoma
1/9/2018 6:06:39 AM Hercules Capital Achieves More Than $880 Mln In New Commitments In 2017
1/4/2018 7:01:46 AM Verastem Appoints Joseph Lobacki As EVP And Chief Commercial Officer
7/11/2014 12:39:29 PM Deutsche Bank Reiterates Verastem, Inc. (VSTM) At Buy With $14 Price Target